Study guide

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs

Key Takeaways Explain This Topic AI

Small molecule Tyrosine Kinase Inhibitors (TKIs) target intracellular catalytic domains of receptor and non-receptor tyrosine kinases (e.g., EGFR, ALK, BRAF/MEK, BCR-ABL, VEGFR), whereas monoclonal antibodies (mAbs) target extracellular ligands or receptor domains.

Antibody-Drug Conjugates (ADCs) utilize a targeted monoclonal antibody linked to a potent cytotoxic payload (e.g., MMAE, DXd) via a stable linker to selectively deliver chemotherapy to antigen-expressing tumor cells.

Class toxicities of targeted therapies require precise clinical monitoring: EGFR inhibitors cause acneiform rash and diarrhea; VEGF/VEGFR inhibitors induce hypertension, proteinuria, and impaired wound healing; PARP inhibitors cause cytopenias and secondary hematologic malignancies.

Pharmacogenomic biomarker screening (e.g., EGFR mutations, ALK rearrangements, BRAF V600E, BRCA1/2 status) is mandatory prior to initiating precision targeted therapy to guide selection and prevent treatment resistance.

Management of ADC-induced interstitial lung disease (ILD)/pneumonitis requires immediate drug discontinuation, prompt initiation of high-dose corticosteroids (prednisone 1-2 mg/kg/day), and comprehensive pulmonary evaluation upon any new or worsening respiratory symptom.

Last updated: August 2026

4.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs

The evolution of systemic cancer therapy from non-specific cytotoxic chemotherapy to precision targeted oncology has transformed the management of solid tumors and hematologic malignancies. Targeted therapies exploit specific genetic alterations, overexpressed cell-surface antigens, or dysregulated intracellular signaling cascades driving oncogenesis. For the Advanced Oncology Certified Nurse Practitioner (AOCNP®), mastering the mechanisms of action, pharmacogenomic biomarker requirements, distinct class toxicity profiles, and evidence-based management algorithms for small molecule inhibitors, monoclonal antibodies, antibody-drug conjugates, and synthetic lethality agents is essential for clinical practice and board certification.

1. Small Molecule Tyrosine Kinase Inhibitors (TKIs) vs. Monoclonal Antibodies

Targeted anti-cancer agents are broadly categorized into small molecule inhibitors (typically designated by the suffix -inib ) and monoclonal antibodies (designated by the suffix -mab ). These drug classes differ fundamentally in molecular weight, mechanism of target engagement, route of administration, and intracellular access.

  • Pharmacologic Property Small Molecule Tyrosine Kinase Inhibitors (TKIs) Monoclonal Antibodies (mAbs)
  • Molecular Weight Low (< 1000 Daltons); synthetic chemical molecules High (~150,000 Daltons); complex proteins

Target Location Intracellular catalytic/kinase domains; intracellular signaling cascades Extracellular cell-surface receptors or circulating soluble ligands

Mechanism of Action Competitive binding to ATP-binding pockets of tyrosine/serine-threonine kinases Receptor blockade, ligand neutralization, antibody-dependent cellular cytotoxicity (ADCC)

Administration Route Oral (tablet/capsule); subject to hepatic CYP450 metabolism Intravenous or subcutaneous; metabolized via catabolism to amino acids

Half-Life Short (hours to days); requires daily oral dosing Long (days to weeks); dosed intermittently (e.g., every 1 to 3 weeks)

Example Agents Osimertinib, alectinib, dabrafenib, imatinib, cabozantinib Trastuzumab, rituximab, cetuximab, bevacizumab

2. Key Tyrosine Kinase Inhibitors & Biomarker-Driven Therapy

Tyrosine kinase inhibitors bind to specific intracellular kinase catalytic sites, blocking downstream signal transduction pathways necessary for tumor cell proliferation, survival, and angiogenesis. Selection of TKI therapy mandates baseline pharmacogenomic testing using next-generation sequencing (NGS), polymerase chain reaction (PCR), or fluorescence in situ hybridization (FISH).

Major TKI Classes & Clinical Applications

Epidermal Growth Factor Receptor (EGFR) Inhibitors : First-generation (erlotinib, gefitinib), second-generation (afatinib), and third-generation (osimertinib) TKIs target EGFR mutation-positive non-small cell lung cancer (NSCLC). Osimertinib selectively inhibits classical EGFR sensitizing mutations (exon 19 deletion, L858R) as well as the exon 20 T790M resistance mutation , and serves as the preferred first-line therapy due to superior central nervous system (CNS) penetration.

Anaplastic Lymphoma Kinase (ALK) Inhibitors : Alectinib, brigatinib, and lorlatinib target ALK gene rearrangements (e.g., EML4-ALK fusion) in NSCLC. Lorlatinib demonstrates robust activity against acquired ALK resistance mutations (such as G1202R) and CNS metastases.

BRAF / MEK Inhibitor Combinations : Dual inhibition of BRAF (dabrafenib, encorafenib) and MEK (trametinib, binimetinib) targets the MAPK/ERK pathway in BRAF V600E/K-mutant melanoma, NSCLC, and colorectal cancer. Combined BRAF/MEK inhibition significantly reduces the paradoxically induced cutaneous squamous cell carcinomas seen with single-agent BRAF monotherapy.

BCR-ABL Kinase Inhibitors : Imatinib, dasatinib, nilotinib, and ponatinib target the BCR-ABL fusion protein resulting from the t(9;22) Philadelphia chromosome in chronic myeloid leukemia (CML). Ponatinib is uniquely effective against the recalcitrant T315I gatekeeper mutation .

Vascular Endothelial Growth Factor Receptor (VEGFR) Multikinase Inhibitors : Cabozantinib, lenvatinib, sunitinib, and pazopanib inhibit VEGFR-1/2/3, platelet-derived growth factor receptors (PDGFR), and RET/MET, disrupting tumor angiogenesis in renal cell carcinoma (RCC), hepatocellular carcinoma, and thyroid cancer.

  • 3. Antibody-Drug Conjugates (ADCs) & Synthetic Lethality
  • Architecture & Mechanism of ADCs

Antibody-Drug Conjugates (ADCs) represent an innovative targeted therapeutic modality designed to deliver highly potent cytotoxic payloads directly to tumor cells while minimizing off-target systemic toxicity. An ADC consists of three structural components:

Targeting Monoclonal Antibody : Binds selectively to a tumor-associated cell-surface antigen (e.g., HER2, TROP-2, Nectin-4, CD30, CD22).

Chemical Linker : A stable peptide or non-cleavable linker that prevents premature payload release in circulation but releases the payload upon intracellular internalization.

Cytotoxic Payload : Highly potent cell-killing agents—such as microtubule inhibitors (monomethyl auristatin E [MMAE]) or topoisomerase I inhibitors (deruxtecan [DXd], SN-38)—that are far too toxic for administration as free systemic chemotherapy.

Upon binding the target antigen, the ADC-antigen complex is internalized via receptor-mediated endocytosis into lysosomes, where lysosomal enzymes cleave the linker, releasing the payload. Payloads with high membrane permeability exert a bystander killing effect , diffusing into adjacent antigen-negative tumor cells within the tumor microenvironment.

ADC Agent Target Antigen Cytotoxic Payload Primary Oncology Indications

Trastuzumab deruxtecan (T-DXd) HER2 (ERBB2) Topoisomerase I inhibitor (DXd) HER2-positive & HER2-low metastatic breast cancer, HER2+ gastric & NSCLC

Sacituzumab govitecan TROP-2 Topoisomerase I inhibitor (SN-38) Triple-negative breast cancer (TNBC), HR+/HER2- breast cancer, urothelial carcinoma

Enfortumab vedotin Nectin-4 Microtubule inhibitor (MMAE) Locally advanced or metastatic urothelial (bladder) carcinoma

Brentuximab vedotin CD30 Microtubule inhibitor (MMAE) Hodgkin lymphoma, systemic anaplastic large cell lymphoma (ALCL)

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors & Synthetic Lethality

PARP inhibitors ( olaparib, rucaparib, niraparib, talazoparib ) exploit the concept of synthetic lethality in tumor cells possessing homologous recombination deficiency (HRD), particularly those harboring deleterious germline or somatic BRCA1 or BRCA2 mutations. PARP enzymes repair single-strand DNA breaks via base excision repair. Inhibiting PARP leads to the accumulation of unrepaired single-strand breaks, which collapse into double-strand DNA breaks during replication. Normal cells repair double-strand breaks via homologous recombination; however, BRCA -deficient cells lack functional homologous recombination and are forced to rely on error-prone non-homologous end joining (NHEJ), resulting in catastrophic genomic instability and cell death.

4. Evidence-Based Toxicity Management Algorithms

Advanced Practice Registered Nurses must recognize and manage distinct targeted therapy toxicity profiles to preserve quality of life and prevent fatal complications.

A. EGFR Inhibitor Cutaneous Toxicity Management

Inhibition of EGFR in epidermal keratinocytes leads to impaired follicular maturation, inflammation, and an acneiform papulopustular rash affecting scalp, face, chest, and upper back in > 80% of patients.

Prophylaxis (Grade 0–1) : Initiate preemptive treatment on Day 1 of EGFR TKI/mAb therapy: hydrocortisone 1% cream applied to face/chest BID, alcohol-free moisturizer, broad-spectrum SPF ≥ 30 sunscreen, and oral doxycycline 100 mg BID (or minocycline 100 mg daily) for 6 to 8 weeks.

Grade 2 Rash (Moderate papulopustules, mild pruritus) : Continue TKI; continue oral doxycycline/minocycline; add topical alclometasone 0.05% or triamcinolone 0.1% cream.

Grade 3 Rash (Severe, confluent, ulcerating, superinfected) : Hold EGFR TKI; administer oral doxycycline plus short-course oral prednisone (0.5 mg/kg/day for 7 days); obtain bacterial cultures; resume TKI at one reduced dose level upon improvement to ≤ Grade 1.

B. VEGF / VEGFR Cardiovascular Toxicities

VEGF pathway inhibition impairs endothelial cell maintenance, decreases nitric oxide production, and causes renal microvascular injury.

Hypertension : Baseline BP screening mandatory. Initiate anti-hypertensive therapy (ACE inhibitors/ARBs or dihydropyridine calcium channel blockers like amlodipine) for BP ≥ 130/80 mmHg or increase of ≥ 20 mmHg diastolic. Avoid non-dihydropyridine CCBs (diltiazem, verapamil) due to CYP3A4 inhibition.

Proteinuria & Bleeding : Dipstick urinalysis prior to each cycle; hold VEGF inhibitor for 24-hour urine protein ≥ 2 grams; permanently discontinue for nephrotic syndrome. Discontinue therapy 28 days prior to elective surgery to prevent surgical wound dehiscence.

C. ADC-Associated Interstitial Lung Disease (ILD) / Pneumonitis

ILD/pneumonitis is a potentially fatal class effect of topoisomerase-I payload ADCs (particularly Trastuzumab deruxtecan).

Grade 1 (Asymptomatic, radiographic change only) : Permanently interrupt T-DXd. Initiate systemic corticosteroids (prednisone 0.5–1 mg/kg/day) until resolution. Monitor CT scans closely. If fully resolved within 28 days, T-DXd may be resumed with cautious monitoring; otherwise, permanently discontinue.

Grade 2 (Symptomatic: new/worsening cough, dyspnea, fever, hypoxia) : Permanently discontinue ADC . Immediately initiate systemic corticosteroids ( prednisone 1 mg/kg/day or equivalent). Taper steroids slowly over at least 4 weeks. Consult Pulmonology and perform high-resolution chest CT.

Grade 3–4 (Severe respiratory compromise, supplemental O2 required) : Permanently discontinue ADC. Hospitalize patient immediately; administer IV methylprednisolone 1–2 mg/kg/day. Consider empirical broad-spectrum coverage and ICU admission.

Loading diagram... Intracellular vs. Extracellular Targeted Therapy Mechanisms